Topotecan, a new active drug in the second-line treatment ...
Topotecan showed significant activity in SCLC, especially in patients sensitive to prior chemotherapy, with manageable toxicity. Response rates were 6.4% in refractory and 37.8% in sensitive groups. Median survival was 5.4 months overall, 4.7 for refractory, and 6.9 for sensitive patients. Toxicity was mainly hematologic.
Reference News
Topotecan, a new active drug in the second-line treatment ...
Topotecan showed significant activity in SCLC, especially in patients sensitive to prior chemotherapy, with manageable toxicity. Response rates were 6.4% in refractory and 37.8% in sensitive groups. Median survival was 5.4 months overall, 4.7 for refractory, and 6.9 for sensitive patients. Toxicity was mainly hematologic.